Literature DB >> 24965163

Patterns of recurrence following selective intraoperative radiofrequency ablation as an adjunct to hepatic resection for colorectal liver metastases.

Karim M Eltawil1, Nana Boame, Richard Mimeault, Wael Shabana, Fady K Balaa, Derek J Jonker, Tim R Asmis, Guillaume Martel.   

Abstract

BACKGROUND AND OBJECTIVES: The purpose of this study was to analyze the patterns of recurrence following intraoperative radiofrequency ablation (RFA) combined with hepatic resection for patients with colorectal liver metastases (CLM).
METHODS: Patients undergoing liver resection (with or without RFA) for CLM were examined. Rates and patterns of disease recurrence, as well as overall survival were assessed using Kaplan-Meier and Cox analyses.
RESULTS: A total of 174 patients underwent liver resection for CLM (150 without and 24 with intraoperative RFA). RFA was used to treat 41 tumors (median 1.6 cm). The 3-year overall survival was 65.5% and 61.4% (adjusted HR 1.02, 95% CI 0.55-1.88). Median recurrence-free survival was 7.4 versus 12.7 months with RFA versus non-RFA, respectively (adjusted HR 1.51, 95% CI 0.94-4.42). On multivariate analysis, neither survival nor recurrence-free survival was significantly associated with RFA. In total, there were two RFA ablation zone local failures. An ablation site recurrence was the sole site in one patient (4.2%).
CONCLUSION: RFA was used as an adjunct to resection in patients with greater disease burden. Despite this, RFA was not significantly associated with a higher risk of local failure and was not associated with worse survival, when compared with liver resection alone.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  colorectal cancer; liver resection; metastasis; radiofrequency ablation; recurrence

Mesh:

Year:  2014        PMID: 24965163     DOI: 10.1002/jso.23689

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  15 in total

1.  Fully laparoscopic thermo-ablation of liver malignancies with or without liver resection: tumor location is an independent local recurrence risk factor.

Authors:  Geoffrey Ledoux; Koceila Amroun; Rami Rhaiem; Audrey Cagniet; Arman Aghaei; Olivier Bouche; Christine Hoeffel; Daniele Sommacale; Tullio Piardi; Reza Kianmanesh
Journal:  Surg Endosc       Date:  2020-02-19       Impact factor: 4.584

Review 2.  Thermal Ablation of Metastatic Colon Cancer to the Liver.

Authors:  Juan C Camacho; Elena N Petre; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 3.  Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis.

Authors:  Giovanni Brandi; Stefania De Lorenzo; Margherita Nannini; Stefania Curti; Marta Ottone; Filippo Gustavo Dall'Olio; Maria Aurelia Barbera; Maria Abbondanza Pantaleo; Guido Biasco
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

4.  Assessment of Liver Remnant Using ICG Clearance Intraoperatively during Vascular Exclusion: Early Experience with the ALIIVE Technique.

Authors:  Lawrence Lau; Christopher Christophi; Mehrdad Nikfarjam; Graham Starkey; Mark Goodwin; Laurence Weinberg; Loretta Ho; Vijayaragavan Muralidharan
Journal:  HPB Surg       Date:  2015-05-27

5.  Prognostic Factors in Terms of the Number of Metastatic Nodules in Patients With Colorectal Cancer Liver Metastases.

Authors:  Ki Ung Jang; Chan Wook Kim; Ki-Hun Kim; Seok-Byung Lim; Chang Sik Yu; Tae Won Kim; Pyo Nyun Kim; Jong Hoon Kim; Jin Cheon Kim
Journal:  Ann Coloproctol       Date:  2016-06-30

6.  Non-response to preoperative chemotherapy is a contraindication to hepatectomy plus radiofrequency ablation in patients with colorectal liver metastases.

Authors:  Rui Mao; Jian-Jun Zhao; Hong Zhao; Ye-Fan Zhang; Xin-Yu Bi; Zhi-Yu Li; Jian-Guo Zhou; Xiao-Long Wu; Chen Xiao; Jian-Qiang Cai
Journal:  Oncotarget       Date:  2017-09-05

7.  Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial.

Authors:  Robbert S Puijk; Alette H Ruarus; Laurien G P H Vroomen; Aukje A J M van Tilborg; Hester J Scheffer; Karin Nielsen; Marcus C de Jong; Jan J J de Vries; Babs M Zonderhuis; Hasan H Eker; Geert Kazemier; Henk Verheul; Bram B van der Meijs; Laura van Dam; Natasha Sorgedrager; Veerle M H Coupé; Petrousjka M P van den Tol; Martijn R Meijerink
Journal:  BMC Cancer       Date:  2018-08-15       Impact factor: 4.430

8.  Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases.

Authors:  Serge Evrard; Graeme Poston; Peter Kissmeyer-Nielsen; Abou Diallo; Grégoire Desolneux; Véronique Brouste; Caroline Lalet; Frank Mortensen; Stefan Stättner; Stephen Fenwick; Hassan Malik; Ioannis Konstantinidis; Ronald DeMatteo; Michael D'Angelica; Peter Allen; William Jarnagin; Simone Mathoulin-Pelissier; Yuman Fong
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

9.  FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION.

Authors:  Felipe José Fernandez Coimbra; Heber Salvador de Castro Ribeiro; Márcio Carmona Marques; Paulo Herman; Rubens Chojniak; Antonio Nocchi Kalil; Evanius Garcia Wiermann; Sandro Roberto de Araújo Cavallero; Fabricio Ferreira Coelho; Paulo Henrique de Souza Fernandes; Anderson Arantes Silvestrini; Maria Fernanda Arruda Almeida; Antônio Luis Eiras de Araújo; Marcos Pitombo; Heberton Medeiros Teixeira; Fábio Luiz Waechter; Fábio Gonçalves Ferreira; Alessandro Landskron Diniz; Giuseppe D'Ippolito; Giuseppe D'Ippolito; Maria Dirlei F de Sousa Begnami; Gabriel Prolla; Silvio Márcio Pegoraro Balzan; Thiago Bueno de Oliveira; Luís Arnaldo Szultan; Javier Lendoire; Orlando Jorge Martins Torres
Journal:  Arq Bras Cir Dig       Date:  2015 Nov-Dec

10.  Radiofrequency ablation is beneficial in simultaneous treatment of synchronous liver metastases and primary colorectal cancer.

Authors:  Joost Hof; Hanneke J Joosten; Klaas Havenga; Koert P de Jong
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.